NEW YORK ( TheStreet) -- TheStreet's Debra Borchardt is with Francis Gaskins, Director of Research for Equities.com, discussing the three biotech IPOs this week.

BlueBirdBio ( BLUE) has a $75 million offering and just completed a deal with Celgene ( CELG), which bodes well for the company, Gaskins says.

BlueBirdBio focuses on cancer treatment by taking a patient's blood and modifying it to attack cancer cells, which could be a huge breakthrough for the industry. According to Gaskins, it is possible for the company to succeed on its own, but the deal with bio-giant Celgene will certainly help.

PTC Pharmaceuticals ( PTCT) also has its IPO this week with a $100 million offering. This company focuses on treating muscular diseases and has a low valuation, at just 2.5 times book value.

While Gaskins says that he still prefers BlueBirdBio to PTC, he likes that this company has several partnerships and that it is "making progress in an area for which there is little known treatment."

Unfortunately for Regado ( RDGO), the company has no collaborations with other biotech names, meaning that they will have no support and will have to do everything on their own.

Making things a little more dicey according to Gaskins, is that the company plans to use the $75 million offering to fund a phase three trial, which has yet to provide a completion date.

While the first two trials have seemed to go well and the valuation is low, Gaskins warns potential investors that without any collaborations or a set completion date for phase three trialing, this name is riskier than the first two.
Bret Kenwell currently writes, blogs and also contributes to Rocco Pendola's Weekly Options Newsletter. Focuses on short- to intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

If you liked this article you might like

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017